Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$734M |
| 2 |
Adobe
ADBE
|
+$488M |
| 3 |
Merck
MRK
|
+$443M |
| 4 |
Tesla
TSLA
|
+$366M |
| 5 |
AGN
Allergan plc
AGN
|
+$315M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$682M |
| 2 |
Perrigo
PRGO
|
+$585M |
| 3 |
Gilead Sciences
GILD
|
+$556M |
| 4 |
EMC
EMC CORPORATION
EMC
|
+$432M |
| 5 |
Morgan Stanley
MS
|
+$401M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.94% |
| 2 | Consumer Discretionary | 14.99% |
| 3 | Communication Services | 11.27% |
| 4 | Technology | 9.94% |
| 5 | Financials | 9.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
Copa Holdings
CPA
$5.56B
| $18.5M | 0.02% |
115,801
-2,390
| -2% | -$361K |
|
|
CMO
452
DELISTED
Capstead Mortgage Corp.
CMO
| $18.4M | 0.02% |
1,524,419
+398,870
| +35% | +$4.76M |
|
|
JIVE
453
DELISTED
Jive Software, Inc.
JIVE
| $18M | 0.02% |
1,600,685
-1,796,706
| -53% | -$20.3M |
|
|
CHC
454
DELISTED
CHINA HYDROELECTRIC CORP SPONSORED ADR RPSTG 3 ORD SHS
CHC
| $17.5M | 0.02% |
6,535,971
| – | – |
|
455
PTC Therapeutics
PTCT
$6.18B
| $17.4M | 0.02% |
1,025,917
+669,544
| +188% | +$11.8M |
|
456
WSFS Financial
WSFS
$4.14B
| $17.3M | 0.02% |
669,807
-327,588
| -33% | -$7.65M |
|
|
BLUE
457
DELISTED
bluebird bio
BLUE
| $17M | 0.02% |
62,496
+15,727
| +34% | +$4.39M |
|
|
458
PUT
Bristol-Myers Squibb
BMY
$129B
| $16.7M | 0.02% |
+314,200
| New | +$16M |
|
459
Delta Air Lines
DAL
$56.7B
| $16.5M | 0.02% |
599,633
-1,588,844
| -73% | -$42.7M |
|
460
NETSCOUT
NTCT
$2.83B
| $16M | 0.02% |
541,747
-103,987
| -16% | -$2.94M |
|
461
Cummins
CMI
$83.6B
| $15.8M | 0.02% |
112,187
-415,781
| -79% | -$55.2M |
|
|
VITC
462
DELISTED
VITACOST COM INC COM STK (DE)
VITC
| $15.2M | 0.01% |
2,626,395
-136,083
| -5% | -$917K |
|
|
DMND
463
DELISTED
DIAMOND FOODS, INC.
DMND
| $14.5M | 0.01% |
+561,995
| New | +$13.4M |
|
|
ORBC
464
DELISTED
ORBCOMM, Inc.
ORBC
| $14.5M | 0.01% |
2,281,600
-157,050
| -6% | -$946K |
|
|
ZU
465
DELISTED
ZULILY INC CLASS A COMMON STOCK
ZU
| $14.4M | 0.01% |
+348,261
| New | +$13.3M |
|
|
ANDV
466
DELISTED
Andeavor
ANDV
| $13.8M | 0.01% |
235,405
-117,220
| -33% | -$6.1M |
|
|
DSCI
467
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $13.7M | 0.01% |
1,268,472
+4,010
| +0.3% | +$46.6K |
|
468
Exelixis
EXEL
$13.9B
| $13.5M | 0.01% |
2,205,478
-413,052
| -16% | -$2.28M |
|
|
TEAR
469
DELISTED
TearLab Corporation
TEAR
| $13.5M | 0.01% |
144,255
+34,654
| +32% | +$3.45M |
|
|
AGN
470
CALL
DELISTED
Allergan Inc
AGN
| $13.3M | 0.01% |
+120,000
| New | +$11.5M |
|
|
SGNT
471
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
| $13.1M | 0.01% |
517,524
-22,299
| -4% | -$504K |
|
|
MLU
472
DELISTED
METLIFE, INC. COM EQUITY UNIT
MLU
| $13M | 0.01% |
413,000
| – | – |
|
|
HTSI
473
DELISTED
HARRIS TEETER SUPERMARKETS INC COM STK (NC)
HTSI
| $12.6M | 0.01% |
256,099
-457,653
| -64% | -$22.6M |
|
474
McEwen Inc
MUX
$1B
| $12.4M | 0.01% |
632,733
-35,401
| -5% | -$723K |
|
475
Teledyne Technologies
TDY
$29.2B
| $12.1M | 0.01% |
131,855
-280,407
| -68% | -$25M |
|
Similar funds
Jennison Associates's Q4 2013 Portfolio in Review
As of Q4 2013, Jennison Associates held 759 positions worth $102B, up 6.9% from $95.4B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jennison Associates's Q4 2013 filing shows 79 new, 184 increased, 411 reduced and 54 closed positions. Its largest new stake was Allergan plc: 2,016,619 shares worth $339M. The largest sale was UnitedHealth, an estimated $682M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q4 2013 buy was Allergan plc: 2,016,619 shares worth $339M.
- Jennison Associates added most to Bristol-Myers Squibb in Q4 2013, an estimated $734M increase.
- Jennison Associates's biggest Q4 2013 reduction was UnitedHealth, cutting an estimated $682M.
- Jennison Associates fully exited Perrigo in Q4 2013, selling an estimated $585M.
- Jennison Associates's ten largest holdings make up 20% of its $102B portfolio in Q4 2013.
- Jennison Associates opened 79 new positions and closed 54 in Q4 2013.
- Jennison Associates's portfolio value rose 6.9% quarter-over-quarter to $102B.
Based on Jennison Associates's 13F filing for Q4 2013, filed 10 Feb 2014.